Risks of Malignant Hyperthermia
Malignant hyperthermia is a progressive, life-threatening hypermetabolic crisis that can prove fatal unless recognized early and treated aggressively—the mortality rate is 3-5% even with modern treatment, but approaches 100% without prompt intervention. 1, 2
Immediate Life-Threatening Risks
The acute MH crisis creates a cascade of potentially fatal complications:
Metabolic Catastrophe
- Hypermetabolic state with uncontrolled skeletal muscle calcium release leading to oxygen consumption and CO2 production at rates 2-3 times normal 1
- Severe hyperthermia with core temperature rising >0.5°C every 15 minutes, often exceeding 40°C (104°F) 3
- Profound acidosis (both respiratory and metabolic) from massive CO2 production and lactic acid accumulation 1, 4
Cardiovascular Collapse
- Malignant arrhythmias including ventricular tachycardia and fibrillation 3
- Cardiac arrest from severe hyperkalemia and acidosis 3
- Tented T-waves on ECG indicating dangerous potassium elevation 3
Organ System Failure
- Rhabdomyolysis with massive muscle breakdown—present in 26% of pediatric cases 5
- Acute kidney injury from myoglobinuria (cola-colored urine) and direct tubular toxicity 3
- Multiorgan failure if the hypermetabolic state is not reversed 3
Population-Specific Mortality Risks
Pediatric patients face higher risk: The incidence is 1 in 30,000 children compared to 1 in 100,000 adults, with a documented mortality of 2.9% in pediatric admissions 5, 2. Male patients are disproportionately affected (64.8% of cases) 5.
Risk of Delayed Recognition
A critical pitfall is that 40.5% of pediatric MH cases are treated at non-children's hospitals where staff may have reduced awareness of this rare condition 5. The increasing use of total intravenous anesthesia (TIVA) paradoxically increases risk by reducing clinician familiarity with MH recognition 4.
Genetic and Familial Risks
MH has autosomal dominant inheritance with incomplete penetrance—genetic prevalence is as high as 1:2,750, but clinical incidence is much lower 6. This means:
- Any family member of an affected individual is at risk
- Patients can have multiple uneventful anesthetics before developing MH 4
- Over 50% of cases involve pathogenic RYR1 gene variants 6
Risk Without Treatment
The condition is universally fatal without dantrolene administration and trigger elimination 1. Historical mortality rates approached 70-80% before dantrolene became available; current 3-5% mortality reflects the critical importance of immediate recognition and treatment 2.
Associated Neuromuscular Disease Risks
Patients with certain neuromuscular conditions face compounded risks:
- RYR1-related myopathies carry inherent MH susceptibility 7
- Duchenne and Becker muscular dystrophy patients risk severe rhabdomyolysis and cardiac complications even without true MH 8
- These patients require absolute avoidance of triggering agents unless proven MH-negative by contracture testing 8
Geographic and Resource Risks
Dantrolene unavailability in many Eastern European countries and developing regions dramatically increases MH fatality risk 4. Without this cornerstone therapy, mortality approaches pre-1970s levels.
Key Clinical Caveat
There are no specific clinical features unique to MH—the diagnosis requires recognizing a pattern of signs (unexplained progressive hypercarbia, tachycardia, muscle rigidity, rising temperature) in the context of trigger agent exposure 1, 4. The earliest and most reliable sign is unexplained progressive increase in end-tidal CO2 despite adequate ventilation 1.